• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BCR Gene Record

  • Summary
  • Interactions
  • Claims
  • BCR 613 Druggable GenomeClinically Actionable

    Alternate Names:

    613
    BCR, RHOGEF AND GTPASE ACTIVATING PROTEIN
    BCR
    ALL
    BCR1
    CML
    D22S11
    D22S662
    PHL
    151410
    1014
    ENSG00000186716
    OTTHUMG00000150655
    BE0004743
    P11274
    PA25321
    2755
    NP_004318
    NM_004327
    Renal carcinoma antigen NY-REN-26
    Breakpoint cluster region protein
    BCR activator of RhoGEF and GTPase

    Gene Info:

    GuideToPharmacology Gene Category Name BCR family
    GuideToPharmacology Gene Category ID 874
    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    TUMOR SUPPRESSOR
    KINASE
    SERINE THREONINE KINASE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Iqbal et al., 2013, Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era., PLoS ONE
    Nadal et al., 2004, Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies., Int. J. Clin. Pract.
    Page BD et al., 2012, Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity., J Med Chem
    Croom et al., 2003, Imatinib mesylate: in the treatment of gastrointestinal stromal tumours., Drugs
    Reddy EP et al., 2012, The ins and outs of bcr-abl inhibition., Genes Cancer
    Waller, 2010, Imatinib mesylate., Recent Results Cancer Res.
    Mojzych M et al., 2014, Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines., Eur J Med Chem
    Adrián FJ et al., 2006, Allosteric inhibitors of Bcr-abl-dependent cell proliferation., Nat Chem Biol
    Shah NP et al., 2004, Overriding imatinib resistance with a novel ABL kinase inhibitor., Science
  • CHEMBL483847   BCR

    Interaction Score: 3.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16415863


    Sources:
    DTC

  • PONATINIB HYDROCHLORIDE   BCR

    Interaction Score: 2.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Breakpoint cluster region protein inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BLINATUMOMAB   BCR

    Interaction Score: 1.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • OMACETAXINE MEPESUCCINATE   BCR

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PONATINIB   BCR

    Interaction Score: 0.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Fusion protein BCR:ABL1
    Notes Pan-BCR-ABL

    PMIDs:
    23409026


    Sources:
    FDA PharmGKB DrugBank TALC

  • IMATINIB   BCR

    Interaction Score: 0.77

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Fusion protein BCR:ABL1
    Notes Targets BCR-ABL fusion protein

    PMIDs:
    15206509 22148584 12600228 23226582 20072827 24681986


    Sources:
    DTC FDA PharmGKB DrugBank TALC

  • NILOTINIB   BCR

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • BOSUTINIB   BCR

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    FDA PharmGKB DrugBank

  • BUSULFAN   BCR

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • SARACATINIB   BCR

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes Targets BCR-ABL fusion protein

    PMIDs:
    None found


    Sources:
    TALC

  • DASATINIB   BCR

    Interaction Score: 0.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes Targets BCR-ABL fusion protein
    Fusion protein BCR:ABL1

    PMIDs:
    15256671


    Sources:
    FDA PharmGKB DrugBank TALC

  • VINCRISTINE   BCR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    FDA PharmGKB

  • Ensembl: ENSG00000186716

    • Version: 101_38

    Alternate Names:
    BCR Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • GuideToPharmacology: 613

    • Version: 29-September-2020

    Alternate Names:
    1014 HUGO Gene ID
    1014 HUGO Gene Symbol
    BCR activator of RhoGEF and GTPase HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name BCR family
    GuideToPharmacology Gene Category ID 874

    Gene Categories:
    ENZYME

    Publications:

  • DrugBank: BE0004743

    • Version: 5.1.7

    Alternate Names:
    BCR DrugBank Gene Name
    P11274 UniProt Accession
    613 Entrez Gene Id

    Gene Info:

    Publications:
    Nadal et al., 2004, Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies., Int. J. Clin. Pract.
    Croom et al., 2003, Imatinib mesylate: in the treatment of gastrointestinal stromal tumours., Drugs
    Reddy EP et al., 2012, The ins and outs of bcr-abl inhibition., Genes Cancer

  • NCI: BCR

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Okabe et al., 1992, Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth., Blood

  • DTC: BCR

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Page BD et al., 2012, Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity., J Med Chem
    Mojzych M et al., 2014, Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines., Eur J Med Chem
    Adrián FJ et al., 2006, Allosteric inhibitors of Bcr-abl-dependent cell proliferation., Nat Chem Biol

  • HingoraniCasas: ENSG00000186716

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000186716 Gene Symbol
    BCR Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: BCR

    • Version: 12-May-2016

    Alternate Names:
    BCR Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: BCR1

    • Version: chembl_23

    Alternate Names:
    D22S11 GENE_SYMBOL
    BCR GENE_SYMBOL
    Breakpoint cluster region protein UNIPROT

    Gene Info:

    Publications:

  • PharmGKB: BCR

    • Version: 18-August-2020

    Alternate Names:
    PA25321 PharmGKB ID

    Gene Info:

    Publications:

  • Pharos: BCR

    • Version: 03-September-2020

    Alternate Names:
    Breakpoint cluster region protein Gene Name
    P11274 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • GO: BCR

    • Version: 05-September-2020

    Alternate Names:
    BCR1 GO Gene Synonym
    D22S11 GO Gene Synonym

    Gene Info:

    Gene Categories:
    TUMOR SUPPRESSOR, KINASE, SERINE THREONINE KINASE

    Publications:

  • Tempus: BCR

    • Version: 11-November-2018

    Alternate Names:
    BCR Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: BCR

    • Version: 27-Jun-2013

    Alternate Names:
    613 Gene ID
    ALL dGene Synonym
    BCR1 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, SERINE THREONINE KINASE

    Publications:

  • FoundationOneGenes: BCR

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: BCR

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: BCR

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21